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Extracellular matrix (ECM) molecules and growth factors partici-
pate in regulation of cellular behaviour by binding to specific cell-
surface receptors. Earlier studies have shown that reduced
intercellular adhesion, disturbed differentiation and changes in the
composition of the basement membrane influence the develop-
ment of malignant tumours (Weinstein et al, 1976; Liotta et al,
1986). Heparan sulphate proteoglycans (HSPGs) are macromole-
cules which are present at the cell surface. They are involved in
cell—cell adhesion and the interaction of cells with ECM
(Ruoslahti, 1989). They are also thought to act as coreceptors for
the heparin-binding growth factors (HBGFs), thus participating in
regulation of cell behaviour (reviewed by Bernfield et al, 1992).
Syndecan-1 is a member of a family of cell-surface HSPGs,
which consists of at least four members named syndecans 1 to 4
(Bernfield et al, 1992; Jalkanen et al, 1993). They all have homolo-
gous transmembrane and cytoplasmic domains, but their extracel-
lular domains are different (Bernfield et al, 1992; Jalkanen et al,
1983). Syndecan-1 was originally found on the surface of normal
murine mammary gland epithelial cells (Rapraeger and Bernfield,
1993), and to date it is the most studied member of the syndecan
family. Syndecan-1 is suggested to act as a matrix receptor, because
it binds to various ECM molecules via its heparan sulphate chains
and contacts the cytoskeleton through its cytoplasmic domain
(Elenius et al, 1990). Components of ECM to which syndecan-1 has
been shown to bind include type I, III and V collagen (Koda et al,
1985), fibronectin (Saunders and Bernfield, 1988), thrombospondin
(Sun et al, 1989), tenascin (Salmivirta et al, 1991), amphoterin
(Salmivirta et al, 1992) and laminin (Salmivirta et al, 1994).
Syndecan-1 also binds the basic fibroblast growth factor (bFGF)
(Elenius et al, 1992).
During organogenesis and tissue formation, the expression of
syndecan is strictly regulated and follows morphogenetic rather
than histological boundaries and correlates with the reciprocal
epithelial—mesenchymal interactions (Thesleff et al, 1988; Vainio
et al, 1989). In a normal adult, syndecan-1 is mainly expressed in
epithelial tissue, where the strongest expression is found in strati-
fied epithelia at the cell—cell contacts in epidermal keratinocytes
(Hayashi et al, 1987; Inki et al, 1991), which suggests that
syndecan-1 is involved in intercellular adhesion of keratinocytes.
In keratinocytes, syndecan-1 is localized at the cell surface,
predominantly in the suprabasal cell layers, whereas the basal cell
layer shows only weak expression. Small amounts of syndecan-1
have been shown to be expressed in fibroblasts (Elenius et al,
1992) and endothelial cells (Kojima et al, 1992). The role of
syndecan in wound healing has also been studied, revealing
increased syndecan expression in proliferating and migrating
epithelial cells of the epidermis and in hair follicles and some
expression on the vascular endothelial cells of granulation tissue
proliferation and differentiation, suggesting that syndecan is
involved in growth factor regulation (Elenius et al, 1991; Bernfield
et al, 1992).
Expression of syndecan-1 has been found to be decreased in
cellular transformation models. The DNA-binding protein
encoded by the Wilms￿ tumour-suppressor gene wt 1 has recently
been found to function as a transcriptional activator of syndecan-1
expression (Cook et al, 1997). When syndecan-1 was transfected
into S115 mouse mammary tumour cells, the re-expression of
syndecan-1 restored the epithelial morphology of the S115 cells
(Lepp￿ et al, 1992). Mouse skin exposed to irradiation shows loss
of syndecan-1 expression, and expression switches from the gran-
ular layer to the basal and lower spinous layers after 2 weeks of
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daily irradiation (Liu et al, 1997). Syndecan-1 is found by
immunohistochemistry in keratinizing cells of the horn pearls in
well-differentiated carcinomas, but in poorly differentiated carci-
nomas syndecan-1 expression may be lost (Inki et al, 1992). In
premalignant lesions of stratified epithelia, syndecan-1 is lost from
the basally located, atypical cell layers (Inki et al, 1991). Loss of
syndecan-1 from transformed cells could be one mechanism by
which tumour cells lose their attachment to each other and to the
ECM and become non-responsive to the signals coming from their
microenvironment (Inki et al, 1994a).
There are few data available on the prognostic value of
syndecan expression in human cancer. The two pilot studies
involving 29 and 89 invasive SCC head and neck carcinomas have
suggested that reduced syndecan-1 expression is associated with
poor survival in SCC of the head and neck (Inki et al, 1994b;
Pulkkinen et al, 1997), but to the best of our knowledge syndecan-
1 expression has not been shown to have independent prognostic
value in any type of human cancer, including cancer of the head
and neck. In the present study, we investigated syndecan-1 expres-
sion with 2 syndecan-1 antibodies against human syndecan-1 in a
homogeneously treated series of 175 patients with squamous cell
head and neck carcinoma with a minimum follow-up of 2 years
and found syndecan-1 expression to have prognostic value that
was independent of clinical stage and histological grade.
MATERIALS AND METHODS
Patients
We collected the clinical data on 265 patients with histologically
diagnosed SCC of the head and neck who were treated with
surgery and post-operative irradiation in Helsinki University
Central Hospital during the period from 1975 to 1990. Ninety
patients were excluded because of insufficient data or non-avail-
able paraffin-embedded tissue. The remaining 175 patients had
carcinoma of the larynx (n = 51), the tongue (n = 50), the floor of
the mouth (n = 22), the lower gum (n = 22), the tonsil (n = 15) or
the hypopharynx (n = 15). The data collected for each patient
included age, sex, primary tumour site, tumour size, cervical nodal
status, overall TNM stage, histological grade, treatment and cause
of death. Of the 175 patients, 21 (12%) had stage 1, 29 (17%) stage
II, 81 (46%) stage III and 44 (25%) stage IV cancer, but none had
distant metastases at the time of the diagnosis. The study group
comprised 126 (72%) male and 49 (28%) female patients. The
mean age at the time of the diagnosis was 60 (range 19—86). All
patients were treated with radical surgery and post-operative split-
course radiotherapy to a total dose of 66 Gy and a daily fraction
size of 2.0—2.2 Gy given in five fractions a week for 9 weeks, with
a 3-week rest in the middle of the treatment. The minimum follow-
up time of the patients after the diagnosis was 2 years (range 2—15
years). The overall 2-year survival rate was 63% and the 5-year
survival rate 43%. Staging was done according to the UICC classi-
fication (1978, Table 1).
Histology
The analysis of syndecan-1 expression was made from formalin-
fixed and paraffin-embedded tumour samples using immunohisto-
chemistry. Histology of the tumours was reviewed by one
pathologist (PH), who graded the tumours according to the WHO
classification (Shamugaratnam and Sobin, 1978), except for 12
Table 1 Site and stage distribution of 175 SCCs of the head and neck
Primary tumour Stage n (%)
Larynx
2 6 (12)
3 32 (63)
4 13 (25)
Tongue
1 20 (40)
2 11 (22)
3 16 (32)
4 3 (6)
Oral cavitya
2 9 (20)
3 20 (46)
4 15 (34)
Tonsil
1 1 (7)
2 2 (13)
3 5 (33)
4 7 (47)
Hypopharynx
2 1 (7)
3 8 (53)
4 6 (40)
aSCCs of the lower gum or the floor of the mouth.
Table 2 Association between syndecan-1 expression and seven
clinicopathological factors in SCC of the head and neck (staining with B-B4,
n = 167)a
Factor Percentage of syndecan-
1-positive tumour cells
≤50% >50%
n (%) n (%) P
Histological gradeb
Grade I 15 (30) 35 (70)
Grade II 30 (43) 40 (57)
Grade III 33 (94) 2 (6) <0.0001
Stage
1–2 13 (27) 35 (73)
3–4 75 (63) 44 (37) <0.0001
Nodal status
N0 38 (41) 55 (59)
N1–3 50 (68) 24 (32) 0.0006
Tumour size
T1–2 37 (44) 47 (56)
T3–4 51 (61) 32 (39) 0.02
Karnofsky’s performance status
60–80 49 (52) 46 (48)
90–100 39 (54) 33 (46) 0.74
Width of the surgical resection
marginc
<0.5 cm 43 (52) 40 (48)
0.5–2.0 cm 43 (53) 38 (47) 0.87
Gender
Male 63 (53) 57 (47)
Female 25 (53) 22 (47) 0.94
aEight slides were excluded because of technical reasons. bTwelve
carcinomas were of a non-keratinizing type and were not graded. cThree
cases had incomplete data.560 A Anttonen et al
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samples which were classified as non-keratinizing carcinomas and
were not graded.
Immunohistochemistry
Syndecan-1 was studied from paraffin-embedded samples by
immunohistochemistry using both a mouse monoclonal antibody
against human syndecan-1 (B-B4, Serotec, Oxford, UK) and a
specific rat monoclonal antibody 104—9 (produced by Dr M
Jalkanen￿s group) against human syndecan-1- derived peptide
(amino acid residues 88—110). All 175 samples were successfully
stained with the 104—9 antibody and 167 slides with the B-B4 anti-
body (8 slides were excluded because of technical reasons).
Tissue samples were cut into 5-mm sections on Vectabond
slides. The slides were kept at +37°C for up to 24 h and then
deparaffinized and dehydrated. The avidin—biotin immunoperoxi-
dase method was used. Pretreated slides were incubated with 2%
normal goat serum in 1% bovine serum albumin (BSA; Sigma, St.
Louis, MO, USA) for 20 min at room temperature (RT), followed
by B-B4 or 104—9 antibody in 0.3% BSA overnight at RT at a
concentration of 1:200 (B-B4) or 1:100 (104—9). After washing
twice with phosphate-buffered saline (PBS), the slides were incu-
bated with Vectastain biotinylated anti-mouse IgG (Vector labora-
tories, Burlingame, CA, USA) in the case of B-B4 or biotinylated
anti-rat IgG in the case of 104—9 (Vector laboratories) in 0.3%
BSA for 30 min at RT. The slides were then washed twice with
A
C
B
D
Figure 1 Haematoxylin and eosin-stained sections (A and C) from SCCs of the head and neck, and same sections stained for syndecan-1 by
immunohistochemistry (stained with 104–9 antibody (B and D). Well-differentiated SCC of the tongue (A), in which 100% of the tumour cells show at least some
positivity in staining for syndecan-1, although the staining intensity varies markedly (B). Poorly differentiated SCC of the larynx (C), where none of the tumour
cells are positive for syndecan-1 (D). All magnifications ´360Syndecan-1 in head and neck cancer 561
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PBS, followed by avidin DH—biotinylated horseradish peroxidase
mixture according to the manufacturer￿s instructions (Vector
Laboratories) for 1 h at RT. After incubation, the slides were
washed again twice with PBS, and for colour reaction, the slides
were incubated with 0.02% 3-amino-9-ethylcarbazole (in N,N-
dimethylformamide) and 0.1% hydrogen peroxidase in 0.05 M
acetate buffer, pH 5.0 for 20 min at RT, counterstained with
haematoxylin and mounted. Histologically normal skin was used
as a positive control and stainings without the primary antibody
were used as negative controls.
Immunoreactivity of syndecan-1 was assessed visually. First,
the percentage of syndecan-1-positive tumour cells was calculated
from at least five representative fields per slide (Olympus Optical
Company, Tokyo, Japan, ´10 objective, diameter 2.6 mm, area
5.31 mm2). Then, the mean percentage of positive cells per field
was calculated. One representative slide was assessed per case.
Forty slides in both staining groups were reassessed by two of the
investigators (AA and PH) in order to study the inter-observer
variability. The inter-observer variability turned out to be low
between the two observers. The kappa coefficients were 0.62
(B-B4) and 0.65 (104—9), which shows a good agreement between
the observers. Assessment of syndecan expression was done
blindly without any knowledge of the clinical or survival data.
Statistical analysis
Statistical analyses were done by using a BMDP computer
program (BMDP, Statistical software, University of California
Press, LA, USA). Cumulative survival was estimated with the
product-limit method. The Mantel—Cox￿s test was used for
comparison of survival between groups. Frequency tables were
analysed with the Chi-square test. The relative importance of prog-
nostic factors was analysed with Cox￿s proportional hazard regres-
sion analysis (BMDP 2L). All P-values are 2-tailed.
RESULTS
The median percentage of syndecan-1-expressing cancer cells was
50% when staining was performed with the B-B4 antibody. Only
in two cases (1%) were all cancer cells positive for syndecan-1,
and only ten (6%) tumours showed entirely negative staining. The
results were similar independent of site, and 58%, 49%, and 43%
of larynx, tongue and oral cavity carcinomas, respectively, had
†50% of cells that stained positively for syndecan-1.
The percentage of tumour cells positive for syndecan-1 (B-B4)
was >50% more often in well- or moderately well-differentiated
cancers than in the poorly differentiated ones (P < 0.0001, Table 2).
A strong (>50%) syndecan-1 expression was also associated with a
low stage (P < 0.0001), lack of lymph node metastases (P = 0.0006)
and a small primary tumour size (P = 0.02). No association between
syndecan-1 expression and preoperative Karnofsky￿s performance
status, gender or the width of the surgical resection margin was
found (Table 2).
When the series was stained for syndecan-1 with the 104—9 anti-
body instead of B-B4, in 50 (29%) cases the percentage of
syndecan-1-positive tumour cells was 80% or less, in 21 (12%)
cases from 81% to 90% of the cells were positive, in 14 (8%) cases
almost all cancer cells (about 95%) were positive and in 90 (51%)
practically all cancer cells expressed syndecan-1. As, in this
staining, in the majority of cases almost all cancer cells were posi-
tive for syndecan-1, we chose 80% as the cut-off value because it
approximately defined the lowest quartile. Only three (2%)
tumours showed entirely negative staining. Examples of staining
are shown in Figure 1.
When the data obtained by 104—9 were used in the analyses, low
syndecan-1 expression (†80%) was again strongly associated with
Table 3 Association between syndecan-1 expression and seven
clinicopathological factors in SCC of the head and neck (staining with 104–9,
n = 175)
Factor Percentage of syndecan-1-
positive tumour cells
≤80% >80%
n (%) n (%) P
Histological gradea
Grade I 7 (13) 46 (87)
Grade II 16 (21) 59 (79)
Grade III 21 (60) 14 (40) <0.0001
Gender
Male 42 (33) 84 (67)
Female 8 (16) 41 (84) 0.03
Width of the surgical resection
marginb
<0.5 cm 31 (35) 57 (65)
0.5–2.0 cm 19 (23) 65 (77) 0.07
Karnofsky’s performance status
60–80 24 (24) 75 (76)
90–100 26 (34) 50 (66) 0.15
Nodal status
N0 25 (26) 72 (74)
N1–3 25 (32) 53 (68) 0.36
Stage
1–2 13 (26) 37 (74)
3–4 37 (30) 88 (70) 0.63
Tumour size
T1–2 24 (28) 62 (72)
T3–4 26 (29) 63 (71) 0.85
aTwelve carcinomas were of a non-keratinizing type and were not graded.
bThree cases had incomplete data.
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Figure 2 Survival by syndecan-1 expression in 167 patients with SCC of
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a low histological grade (P < 0.0001, Table 3) and also with the
male gender (P = 0.03). However, no association between
syndecan-1 expression and the stage (P = 0.63), the nodal status
(P = 0.36) or the primary tumour size (P = 0.85) was found (Table 3).
Association of syndecan-1 expression with survival
Strong (>50%) syndecan-1 expression was associated with
favourable overall survival (P = 0.001, B-B4 staining, Figure 2).
When the percentage of syndecan-1-positive tumour cells was
over 50%, the 2-year survival rate was 72% and the 5-year survival
rate 56%, whereas, if the percentage of syndecan-1-positive cells
was less than 50%, the corresponding rates were only 50% and
32% respectively. A similar result was found when the SCCs of the
larynx (the largest single subgroup) were analysed separately: a
high (>50%) syndecan-1 expression was associated with
favourable overall survival (P = 0.04, Figure 3). Among patients
with laryngeal cancer, the 2-year survival rate was 81% and the
5-year survival rate 59% if more than 50% of cancer cells stained
positively for syndecan-1, but only 48% and 33%, respectively, if
†50% of cells were positive. When the 104—9 antibody was used, a
strong (>80%) syndecan-1 expression was again associated with
favourable overall survival (P = 0.02, Table 4). If the percentage of
syndecan-1-positive tumour cells was over 80%, the 2-year
survival rate was 66% and, if 80% or less, only 47% (Figure 4).
Several factors other than syndecan-1 expression were signifi-
cantly associated with survival in the series in a univariate survival
analysis (Table 4). These included the clinical stage (P = 0.0002),
nodal status (P = 0.0009), tumour size (P = 0.0002), Karnofsky￿s
performance status (P = 0.006), the width of the surgical margin
(P = 0.02) and histological grade (P = 0.05). In a multivariate
analysis of the entire series, the clinical stage [relative risk (RR)
2.1, 95% confidence interval (CI) 1.2—3.8], expression of
syndecan-1 (B-B4) (RR 1.9, 95% CI 1.2—3.1) and possibly the
width of the surgical margin (RR 1.5, 95% CI 1.0—2.4) had inde-
pendent prognostic value influencing overall survival (Table 5).
When we entered only the SCCs of the larynx into the model,
strong syndecan-1 expression and the width of the surgical margin
turned out to be the only independent factors influencing survival.
The results remained essentially similar when staining with
104—9 was used instead of B-B4 staining in a multivariate
Table 4 Prognostic value of nine factors in SCC of the head and neck
Factor n Two-year P-value
survival (%)
Clinical stage
St 1–2 48 86
St 3–4 119 51 0.0002
Tumour size
T1–2 84 76
T3–4 83 47 0.0002
Nodal status
N0 93 72
N1–3 74 47 0.0009
Syndecan-1 (stained with B-B4)
≤50% 88 50
>50% 79 72 0.001
Karnofsky’s performance status
60–80 95 57
90–100 72 67 0.006
Syndecan-1 (stained with 104–9)
≤80% 50 47
>80% 125 66 0.02
Width of the surgical resection
margina
<0.5 cm 83 54
0.5–2.0 cm 81 67 0.02
Histological gradeb
Grade I 50 71
Grade II 70 57
Grade III 35 53 0.05
Gender
Male 120 61
Female 47 61 0.50
aThree cases had incomplete data. bTwelve carcinomas were of a non-
keratinizing type and were not graded.
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analysis. The clinical stage (RR 2.6, 95% CI 1.5—4.4) and expres-
sion of syndecan-1 (RR 1.7, 95% CI 1.1—2.6) turned out to be the
only independent prognostic factors.
DISCUSSION
In the present study, we investigated the association of syndecan-1
expression with prognosis in SCC of the head and neck. The series
consisted of 175 patients diagnosed with SCC of the head and
neck and treated in a uniform fashion, and syndecan-1 expression
was assessed using both a specific mouse anti-human antibody B-
B4 and a rat monoclonal antibody 104—9 against human syndecan-
1 by immunohistochemistry. Syndecan-1 expression (B-B4) in
more than 50% of cancer cells was associated with favourable
outcome in both a univariate and a multivariate survival analysis,
and it was also associated with a small primary tumour size, lack
of nodal metastases and, in particular, high histological grade of
differentiation. The findings were similar in the entire series and in
the largest subgroup studied (laryngeal cancer). Moreover, essen-
tially similar results were obtained with the 104—9 antibody. The
minor difference between the results obtained with these two anti-
bodies can be explained by their recognition epitopes, which for
B-B4 is the intact cell surface form of syndecan-1, but in the case
of the 104—9 antibody, is the core protein only.
Earlier, we found a low syndecan-1 expression to be associated
with poor survival, in a much smaller series consisting of only 29
patients, using a polyclonal affinity-purified rabbit antibody (anti-
P117) that works only in unfixed tissue (Inki et al, 1994b). Although
all these staining data with three different anti-syndecan-1 anti-
bodies support the association between low syndecan-1 expression
and poor survival in squamous cell head and neck cancer, it has not
been established how the loss of syndecan-1 contributes to poor
outcome. Normal tissue and well-differentiated SCCs show stronger
syndecan-1 expression than do undifferentiated carcinomas.
According to one hypothesis, syndecan-1 expression is diminished
during malignant transformation and, therefore, soluble growth
factors might reach more easily growth factor receptors located on
the plasma membrane, resulting in more sustained stimulation of the
cell growth. Cells that have lost syndecan-1 may also be more
loosely bound to the extracellular matrix, which may contribute to
metastasis formation.
The role of histological grading as a prognostic factor is not
settled in head and neck cancer. In some studies, histological
grading has been found to have prognostic value (Pera et al, 1986;
Wiernik et al, 1991), while some others disagree (Bundgaard et al,
1992). In the present study, a low histological grade of differentia-
tion was only marginally associated with unfavourable overall
survival (P = 0.05). Although histological grading is generally
considered to be a prognostic factor in head and neck cancer, it is
subjective and, therefore, often difficult to reproduce (Bundgaard
et al, 1992). Syndecan-1 expression may be a valuable adjunct to
histological grading, because we found a high degree of unifor-
mity in assessment of syndecan-1 expression between the two
classifiers, and syndecan-1 expression appears to be associated at
least as strongly with prognosis as is histological grading. Reliable
methods for assessment of the biological aggressiveness of head
and neck cancer are becoming more and more important because
there is now evidence that the novel aggressive treatments, such as
chemotherapy given concomitantly or alternating with radio-
therapy (El-Sayed et al, 1996; Benasso et al, 1997), or the new
radiotherapy fractionation schemes (Horiot et al, 1992), may result
in improved survival.
In conclusion, decreased expression of syndecan-1 is associated
with low histological grade of differentiation and poor outcome in
SCC of the head and neck treated with surgery and post-operative
radiotherapy. In the present series, syndecan-1 expression was the
only independent prognostic factor together with the clinical stage.
Hence, syndecan-1 expression appears to be a novel prognostic
factor in head and neck cancer. Its role as a predictive and prognostic
factor in other types of human cancer now need to be explored.
Table 5 Results of Cox’s stepwise proportional hazard model in SCC of the head and neck
Factor b s.e. b/s.e.a P RRb Step of
(95%<1) removal
Clinical stage
(3–4 vs 1–2) 0.75 0.30 2.46 <0.001 2.1 (1.2–3.8) 1
Syndecan-1 expression
(B-B4)
(≤50% vs >50%) 0.65 0.24 2.72 0.016 1.9 (1.2–3.1) 2
Width of the surgical margin
(<0.5 cm vs 0.43 0.23 1.91 0.055 1.5 (1.0–2.4) 3
0.5–2.0 cm)
Histological grade
(III vs II vs I) NSc
Karnofsky’s status
(≤80 vs >80) NS
Tumour size
(T3–4 vs T1–2) NS
Nodal status
(N1–3 vs N0) NS
ab is the estimated regression coefficient of the hazard function, s.e. is the standard error and b/s.e. describes their significance. bRR is the relative risk,
95% confidence limits are given for the relative risk of death. cNS not significant.564 A Anttonen et al
British Journal of Cancer (1999) 79(3/4), 558–564 © Cancer Research Campaign 1999
ACKNOWLEDGEMENTS
We thank associate professor Seppo Sarna for advice on statistical
analysis, Dr Veli-Matti Wasenius, Mrs P￿ivi Laurila, Mrs P￿ivi
Tainola, Ms P￿ivi Heino, Ms Kati Konola and Mrs Elina Roimaa
for technical advice and docent Pekka Virkkunen for help in
preparing the figures. This study was supported by the Cancer
Society of Finland and the Academy of Finland
REFERENCES
Benasso M, Bonelli L, Numico G, Corvo R, Sanguineti G, Rosso R, Vitale V and
Merlano M (1997) Treatment with cisplatin and fluorouracil alternating with
radiation favourably affects prognosis of inoperable squamous cell carcinoma
of the head and neck: results of a multivariate analysis on 273 patients. Ann
Oncol 8: 773—779
Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL and Lose E
(1992) Biology of syndecans. Annu Rev Cell Biol 8: 365—393
Bundgaard T, S¿rensen FB, Gaihede M, S¿gaard H and Overgaard J (1992)
Stereometric, histopathologic, flow cytometric and clinical parameters in the
prognostic evaluation of 74 patients with intraoral squamous cell carcinomas.
Cancer 70: 1—13
Cook DM, Hinkes MT, Bernfield M and Rausher FL III (1997) Transcriptional
activation of the syndecan-1 promoter by the Wilms￿ tumor protein WT1.
Oncogene 13: 1789—1799
Elenius K, Salmivirta M, Inki P, Mali M and Jalkanen M (1990) Binding of human
syndecan to extracellular matrix proteins. J Biol Chem 29: 17837—17843
Elenius K, Vainio S, Laato M, Salmivirta M, Thesleff I and Jalkanen M (1991)
Induced expression of syndecan in healing wounds. J Cell Biol 114: 585—595
Elenius K, M￿￿tt￿ A, Salmivirta M and Jalkanen M (1992) Growth factors induce
3T3 cells to express bFGF-binding syndecan. J Biol Chem 25: 6435—6441
El-Sayed S and Nelson N (1996) Adjuvant and adjunctive chemotherapy in the
management of squamous cell carcinoma of the head and neck region. A meta-
analysis of prospective and randomized trials. J Clin Oncol 14: 838—847
Hayashi K, Hayashi M, Jalkanen M, Firestone JH, Trelstad RL and Bernfield M
(1987) Immunocytochemistry of cell surface heparan sulfate proteoglycan in
mouse tissue. A light and electron microscopic study. J Histochem Cytochem
35: 1079—1088
Horiot JC, Le Fur R, N￿guyen T, Chenal C, Schraub S, Alfonsi S, Gardani G, Van
Den Bogaert W, Danzak S, Bolla M, Van Glabbeke M and De Pauw M (1992)
Hyperfractionation versus conventional fractionation in oropharyngeal
carcinoma: final analysis of a randomized trial of the EORTC cooperative
group of radiotherapy. Radiother Oncol 25: 231—241
Inki P, Stenb￿ck F, Talve L and Jalkanen M (1991) Immunohistochemical
localization of syndecan in mouse skin tumors induced by UV irradiation.
Am J Pathol 139: 1333—1340
Inki P, Kujari H and Jalkanen M (1992) Syndecan in carcinomas produced from
transformed epithelial cells in nude mice. Lab Invest 66: 314—323
Inki P, Larjava H, Haapasalmi K, Miettinen H, Grenman R and Jalkanen M (1994a)
Expression of syndecan-1 is induced by differentiation and suppressed by
malignant transformation of human keratinocytes. Eur J Cell Biol 63: 43—51
Inki P, Joensuu H, Grenman R, Klemi P and Jalkanen M (1994b) Association
between syndecan-1 expression and clinical outcome in squamous cell
carcinoma of the head and neck. Br J Cancer 70: 319—323
Jalkanen M, Elenius K and Rapraeger A (1993) Syndecan: regulator of cell
morphology and growth factor action at the cell—matrix interface. Trends
Glycosci Glycotechn 5: 107—120
Koda J, Rapraeger A and Bernfield M (1985) Heparan sulfate proteoglycans from
mouse mammary epithelial cells. Cell surface proteoglycan as a receptor for
interstitial collagens. J Biol Chem 260: 8157—8162
Kojima T, Scworak NW and Rosenberg RD (1992) Molecular cloning and
expression of two distinct cDNAs encoding heparan sulfate proteoglycan core
proteins from a rat endothelial cell line. J Biol Chem 267: 4870—4877
Lepp￿ S, Mali M, Miettinen H and Jalkanen M (1992) Syndecan expression
regulates cell morphology and growth of mouse mammary epithelial tumor
cells. Proc Natl Acad Sci USA 89: 932—936
Liotta LA, Rao CN and Wewer UM (1986) Biochemical interactions of tumor cells
with the basement membrane. Annu Rev Biochem 55: 1037—1051
Liu K, Kasper M, Bierhaus A, Langer S, Peterson I, Muller M and Trott KR (1997)
Differential expression of CD44 and CD44v10 proteins and syndecan in
normal and irradiated mouse epidermis. Histochem Clee Biol 107: 159—167
Pera E, Moreno A and Galino L (1986) Prognostic factors in laryngeal carcinoma.
Cancer 58: 928—934
Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P and Grenman R (1997) Syndecan-
1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol (Stockh) 117:
312—315
Rapraeger A and Bernfield M (1983) Heparan sulfate proteoglycans from mouse
mammary epithelial cells. A putative membrane proteoglycan associates
quantitatively with lipid vesicles. J Biol Chem 258: 3632—3636
Ruoslahti E (1989) Proteoglycans in cell regulation. J Biol Chem 264: 13369—13372
Salmivirta M, Elenius K, Vainio S, Hofer U, Chiquet-Erismann R, Thesleff I and
Jalkanen M (1991) Syndecan from embryonic tooth mesenchyme binds
tenascin. J Biol Chem 266: 7733—7739
Salmivirta M, Rauvala H, Elenius K and Jalkanen M (1992) Neurite growth-
promoting protein (amphoterin, p30) binds syndecan. Exp Cell Res 200:
444—451
Salmivirta M, Mali M, Heino J, Hermonen J and Jalkanen M (1994) A novel
laminin-binding form of syndecan-1 (cell surface proteoglycan) produced by
syndecan-1 cDNA-transfected NIH-3T3 cells. Exp Cell Res 215: 180—188
Saunders S and Bernfield M (1988) Cell surface proteoglycan binds mouse
mammary epithelial cells to fibronectin and behaves as a receptor on interstitial
matrix. J Cell Biol 106: 423—430
Shanmugaratnam K and Sobin LH (eds) (1978) Histological Typing of Upper
Respiratory Tract Tumours, pp. 14—33. WHO: Geneva
Sun X, Mosher DF and Rapraeger A (1989) Heparan sulfate-mediated binding of
epithelial cell surface proteoglycan to thrombospondin. J Biol Chem 264:
2885—2889
Thesleff I, Jalkanen M, Vainio S and Bernfield M (1988) Cell surface proteoglycan
expression correlates with epithelial—mesenchymal interaction during tooth
morphogenesis. Dev Biol 129: 565—572
Vainio S, Lehtonen E, Jalkanen M, Bernfield M and Saxen L (1989)
Epithelial—mesenchymal interactions regulate the stage-specific expression of a
cell surface proteoglycan, in the developing kidney. Dev Biol 134: 382—391
Weinstein RS, Merk FB and Alroy J (1976) The structure and function of
intercellular junctions in cancer. Adv Cancer Res 23: 25—33
Wiernik G, Millard PR and Haybittle JL (1991) The predictive value of histological
classification into degrees of differentiation of squamous cell carcinoma of the
larynx and hypopharynx compared with the survival of patients.
Histopathology 19: 411—417